During a TV3 program, Prime Minister Siliņa was questioned about funding for cancer treatment, noting that this year no additional funds were allocated, leading patient organizations to declare the situation critical. She highlighted that under her government, state co-funding and the budget for reimbursable oncology medications have substantially increased, citing nearly double the funding for these drugs. Despite Siliņa's assertion regarding the availability of innovative cancer drugs in Latvia, data indicates a different reality.

Innovative medications, which feature new active ingredients or distinct mechanisms of action, typically hold a status of being 'innovative' as long as they are protected by data and market exclusivity without generic counterparts. However, studies published last year indicate that Latvia and Lithuania together accounted for only 14% of the cancer medications registered in the European Union over recent years. This statistic suggests that Siliņa's claim may not accurately reflect the current landscape of cancer treatment in the Baltic states.

The discrepancy between the Prime Minister's claims and the actual availability of innovative treatments could have significant implications for public trust and healthcare policy in Latvia. With the patient organizations raising alarms about critical funding issues, there may be pressure on the government to reassess its budget and strategies for cancer care to ensure that patients receive the best possible treatments without being misled by political assertions.